What is HC Wainwright’s Estimate for RMTI FY2026 Earnings?

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities researchers at HC Wainwright decreased their FY2026 earnings per share estimates for shares of Rockwell Medical in a report released on Friday, September 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.90) per share for the year, down from their previous forecast of ($0.76). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at $0.08 EPS and Q3 2027 earnings at $0.12 EPS.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10). The firm had revenue of $17.78 million for the quarter, compared to analysts’ expectations of $17.82 million. Rockwell Medical had a negative net margin of 7.33% and a negative return on equity of 14.03%.

A number of other research firms have also recently commented on RMTI. Weiss Ratings upgraded shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 3rd. Wall Street Zen raised Rockwell Medical to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $20.00.

Rockwell Medical Stock Down 2.3%

Shares of Rockwell Medical stock opened at $7.78 on Tuesday. The company has a 50-day simple moving average of $7.17 and a two-hundred day simple moving average of $7.83. The stock has a market capitalization of $31.35 million, a PE ratio of -5.81 and a beta of 1.64. Rockwell Medical has a 52-week low of $4.89 and a 52-week high of $17.20. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.00 and a current ratio of 3.25.

Institutional Investors Weigh In On Rockwell Medical

An institutional investor recently bought a new position in Rockwell Medical stock. Corsair Capital Management L.P. bought a new stake in shares of Rockwell Medical, Inc. (NASDAQ:RMTI) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $45,000. Corsair Capital Management L.P. owned about 0.13% of Rockwell Medical at the end of the most recent quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.